Spontaneous regression of sites of metastatic renal cell carcinoma is a well-described
phenomenon.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spontaneous regression of metastatic renal cell carcinoma.Urology. 1982; 20: 177-181
- Spontaneous regression of metastatic pulmonary renal cell carcinoma in the setting of sarcomatoid differentiation of the primary tumour.Can Urol Assoc J. 2013; 7: E587-E589
- Spontaneous regression of primary and metastatic renal cell carcinoma.J Urol. 1996; 155: 1385
- Spontaneous regression of renal cell carcinoma.Contemp Oncol (Pozn). 2013; 17: 123-127
- Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.Br J Urol. 1989; 63: 128-131
- Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence.Int Urol Nephrol. 1991; 23: 13-25
- Spontaneous regression of biopsy proven primary renal cell carcinoma: a case study.Can Urol Assoc J. 2012; 6: E203-E205
- Spontaneous regression of primary renal cell carcinoma with inferior vena caval tumor thrombus.J Urol. 2002; 167: 242-243
- Spontaneous regression of primary renal cell carcinoma—a case report.Yonsei Med J. 1986; 27: 314-317
- Spontaneous regression of renal cell carcinoma: a pitfall in diagnosis of renal lesions.J Clin Pathol. 1998; 51: 334-336
- Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.EJNMMI Res. 2017; 7: 80
- Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.Clin Nucl Med. 2015; 40: 309-313
- Prospective evaluation of 99mTc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors.Eur Urol. 2016; 69: 413-416
- Diagnostic approach to eosinophilic renal neoplasms.Arch Pathol Lab Med. 2014; 138: 1531-1541
- Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.Eur Urol. 2015; 68: 408-415
- Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry.J Urol. 2018; 169: 641-648
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape.Curr Opin Immunol. 2014; 27: 16-25
- Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.Drug Resist Updat. 2004; 7: 289-300
- Impact of perioperative infection on cancer specific survival after nephrectomy for renal cell carcinoma.J Urol. 2017; 198: 1027-1032
- Recent advances in localized RCC: a focus on VEGF and immuno-oncology therapies.Urol Oncol. 2018; 36: 23-30
Article info
Publication history
Published online: July 20, 2018
Accepted:
July 14,
2018
Received:
July 2,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
